The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan

Launched by NATIONAL HEALTH RESEARCH INSTITUTES, TAIWAN · Aug 29, 2022

Keywords

ClinConnect Summary

This clinical trial, known as the Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan, is investigating genetic changes in a type of throat cancer called oropharyngeal squamous cell carcinoma (OPSCC). The researchers aim to use advanced technology to analyze tumor samples from patients, which could help develop new ways to identify and treat this cancer, particularly in Taiwanese patients who are positive or negative for the human papillomavirus (HPV).

To participate, individuals need to be at least 20 years old and have a confirmed diagnosis of squamous cell carcinoma in the head and neck. They should also have tumor samples from both their original diagnosis and any recurrence of the disease after treatment. Participants will be asked to provide these tumor samples and will be closely monitored throughout the study. It's important that they can understand the study details and are willing to follow up regularly. This trial is currently recruiting participants, so if you or someone you know meets the criteria and is interested in helping advance cancer research, this could be an opportunity to consider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Ages 20 and above
• • 2. Pathological reported as squamous cell carcinoma of head and neck
• • 3. Available p16 immunohistochemical staining status (restricted to the OPSCC subgroup)
• • 4. Participants have both archival tumor tissues from the primary head and neck SCC and from the first recurrent tumor (for the recurrence subgroup)
• • 5. Recurrence status is defined as the reappearance of the disease occurring more than 6 months following curative surgery and/or chemoradiotherapy in the recurrence subgroup
• • 6. Willingness to provide archival or newly obtained tumor tissues for current study proposal
• • 7. Life expectancy more than 3 months
• • 8. Patients fully understand the protocol with the willingness to have regular follow-up
• • Exclusion criteria
• • 1. Inability to cooperate by providing a complete medical history
• • 2. No available tumor tissues for genetic testing
• • 3. Undesirable compliance
• • 4. Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded